Research programme: coronavirus inhibitors - Fulcrum/Johns Hopkins University

Drug Profile

Research programme: coronavirus inhibitors - Fulcrum/Johns Hopkins University

Alternative Names: 3CLpro inhibitors; Coronavirus inhibitors research programme - Fulcrum/Johns Hopkins University; Coronavirus protease inhibitors

Latest Information Update: 13 Nov 2003

Price : $50

At a glance

  • Originator Fulcrum Pharmaceuticals; Johns Hopkins University
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronavirus infections

Most Recent Events

  • 13 Nov 2003 Preclinical trials in Coronavirus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top